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Alcoholic liver disease (ALD) is the most prevalent cause of
advanced liver disease in Europe and is the leading cause of death
among adults with excessive alcohol consumption. There is a
dose-response relationship between the amount of alcohol
consumed and the risk of ALD. The relative risk of cirrhosis
increases in subjects who consume more than 25 g/day. The
burden of alcohol-attributable liver cirrhosis and liver cancer is
high and is entirely preventable. Health agencies should develop
population-based policies to reduce the prevalence of harmful
and/or hazardous alcohol consumption and foster research
in this ﬁeld to provide new diagnostic and therapeutic tools.
Disease progression of patients with ALD is heavily inﬂuenced
by both genetic and environmental factors. Non-invasive meth-
ods for the diagnosis of ﬁbrosis have opened new perspectives
in the early detection of advanced ALD in asymptomatic
patients. Alcoholic hepatitis, the most severe form of ALD, carries
a high short-term mortality (around 30–50% at 3 months).
Corticosteroids improve short-term survival in patients with sev-
ere alcoholic hepatitis but duration of therapy should be adapted
to early response. Liver transplantation is the best option for
patients with severe liver dysfunction. However, alcohol relapse
after transplantation remains a critical issue and drinking habits
of transplanted patients need to be routinely screened.
 2015 Published by Elsevier B.V. on behalf of the European
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[1]. The health consequences of alcohol consumption vary
according to the extent and method of usage (excessive or not,
acute or chronic), and depend on numerous environmental and
individual factors. Demographic characteristics, the amount of
alcohol intake, frequency, duration and proﬁle of consumption
vary among alcohol drinkers [2]. In men, daily drinking is
associated with an increased risk of alcoholic cirrhosis.
Interestingly, recent alcohol consumption rather than earlier in
life consumption is associated with higher risk of alcoholic cir-
rhosis [3]. Alcohol drinkers consuming up to 2 drinks/day
(men) or 1 drink/day (women) are deﬁned as moderate drinkers
and do not disclose increased risk of organ damage compared to
abstainers. Daily consumption above those limits can lead to
health, personal and social problems. This deﬁnition does not
capture the pattern of binge drinking that is quite different from
that of chronic drinkers. There is wide heterogeneity in the def-
inition of binge drinking, according to the threshold of alcohol
intake per episode. The National Institute on Alcohol Abuse and
Alcoholism (NIAAA) proposed a consensual deﬁnition of binge
drinking episodes as the consumption of 5 or more drinks (male)
or 4 or more drinks (female) in about 2 h [4]. This deﬁnition fails
to recognize the amount of alcohol intake per binge episode.
Moreover, the possibility of having several binges during the
same day is not included. Finally, a binge alcohol drinker can
have periods of continuous alcohol use. The phenomenon of
binge drinking continues to grow in Western countries, and is
particularly striking in beer- and spirit-drinking cultures in the
UK and northern Europe [5]. Between 1993 and 2001 in the
USA, binge drinking episodes per person per year increased by
17%, with the highest rates occurring among youth aged 18 to
25 years [6]. In the UK, the Health Survey for England (HSE)
reported that 57% of young males were binge drinkers [7]. Most
European countries exhibit the same trend towards an increase
in binge drinking, even in southern countries. As an example,
one French 17-year-old population reported having had binge
drinking episodes over the previous month, of one, three or ten
times in 45.8%, 17.9%, and 2.2% of cases, respectively [8]. Since
1998, American college students aged 18–24 have had a signiﬁ-
cantly higher increase in alcohol-related deaths than population
totals for the same age group [9]. Thus, public health policies
should be targeted towards young people, though they may be
less receptive to the prevention messages against this pattern
of drinking [10]. Up until now, policies have failed to reduce
binge drinking in adolescents and adults, which remains an15 vol. 62 j S38–S46
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Fig. 1. Relationship between standard liver death rate and overall alcohol
consumption in several European countries. The relationship between standard
liver death rate (SDR) (per 100,000) and overall alcohol consumption (pure
alcohol litres per capita, age 15+) in the four countries in the EU (pre-2004) with
the largest rises or falls in liver deaths between 1970 and 2008. Data from the
World Health Organization, European Health for All database (HFA-DB): http://
data.euro.who.int/hfadb/. Reproduced with permission from [17].
JOURNAL OF HEPATOLOGY
important health objective in Western countries. The question
arises as to whether specialists in liver disease should be con-
cerned by the increase in binge drinkers. However, data concern-
ing the impact of binge drinking on the liver are limited because
it has been insufﬁciently investigated [8,11].
There is a signiﬁcant disparity in the sex distribution of deaths
attributable to excessive alcohol consumption. As an example,
11% of deaths in men and 1.8% in women in Europe are attribu-
table to alcohol [2]. Chronic alcohol consumption may lead to cir-
rhosis and is associated with an increased risk for hepatocellular
carcinoma (HCC) [4]. Alcoholic liver disease (ALD) is the most
prevalent cause of advanced liver disease in Europe and cirrhosis
is the leading cause of death due to alcohol among adults [2].
There is a dose-response relationship between the volume of
alcohol consumed with the risk of ALD. Previous epidemiological
studies strongly suggested a considerable association between
alcohol consumption and cirrhosis and emphasized the
correlation between severity and duration of alcohol abuse and
the presence of cirrhosis. Above a threshold of daily alcohol
consumption, the risk of developing cirrhosis increases
exponentially. However, the threshold value of daily alcohol con-
sumption associated with increased risk of cirrhosis has long
been controversial. The amount of alcohol intake can be
expressed in g/day, number of drinks (each drink contains 14 g
of alcohol) or alcohol units (each unit has 8 g of alcohol in the
UK or 14 g in USA). A meta-analysis observed that consumption
of more than 25 g/day increases the relative risk of cirrhosis
[12]. This threshold has been validated in the Dionysos project
assessing the prevalence of alcoholic cirrhosis in a cohort derived
from a general population of two cities in northern Italy [13]. Six
thousand nine hundred and seventeen adult subjects were asked
about their alcohol consumption. Twenty-one percent of the pop-
ulation had a daily alcohol consumption of more than 30 g/day.
The rate of cirrhosis was signiﬁcantly higher in patients who con-
sumed P30 g/day (2.2%) than among abstainers or those with
consumption <30 g/day: 2.2% vs. 0.08%. The risk of cirrhosis
increased with the amount of alcohol consumed. Subjects who
consumed more than 120 g/day had the highest risk of cirrhosis,
with a prevalence of 13.5%.
Liver diseases are an important cause of global burden of mor-
tality and morbidity [14,15]. The burden of liver diseases in North
America and Europe is mainly attributable to alcohol whereas in
Africa and Asia viral hepatitis is the dominant force. In 2010, cir-
rhosis accounted for more than 493,300 deaths (156,900 female
and 336,400 male deaths) and for more than 14.5 million
DALYs (disability-adjusted life year) (around 4.1 million DALYs
for women and 10.4 million DALYs for men) [14–16]. In addition,
around 82,000 deaths (around 14,000 female and 66,000 male
deaths) and 2.1 million DALYs were due to alcohol-induced liver
cancer [14–16]. The weight of alcohol on liver-related mortality is
strongly supported by data showing a relationship between stan-
dard liver death rate and overall alcohol consumption in several
European countries (Fig. 1) [17].
Variations in alcohol consumption largely contribute to cir-
rhosis mortality trends and its variability across countries
[18,19]. Also, reduction in alcohol consumption in most countries
is followed by a decrease in cirrhosis mortality. In North America,
Australia and Southern Europe alcohol consumption decreased in
recent years, leading to comparable decline in cirrhosis mortality
[18,20–22]. Conversely, the high rates of cirrhosis mortality in
Hungary and other countries of central and Eastern Europe areJournal of Hepatology 201mainly due to their high per capita alcohol consumption [18].
The marked rises in cirrhosis mortality in Ireland and the UK
(particularly Scotland) are related to the fact that total recorded
alcohol consumption in Britain doubled between 1960 and
2002 [10]. Indeed, one study compared age-standardized mortal-
ity rates for cirrhosis in the UK with the rates from 12 Western
European countries for the period between 1955 and 2001 [10].
UK standardized mortality rates for cirrhosis increased in men
from 3.4 between 1957 and 1961, to 14.1 per 100,000 per year
between 1997 and 2001, with the same trend in women, whereas
it decreased in other European countries. Cirrhosis mortality
rates in Scotland are among the highest in Western Europe, with
mortality rates in men and women of 42.2 and 20 per 100,000 per
year, respectively [10]. Another study obtained records of all
patients in a longitudinal database of 13 million subjects fol-
lowed in general practice [23]. This study conﬁrmed a 45%
increase in the incidence of cirrhosis in the UK during the last
decade.
These studies indicate that the burden of alcohol-attributable
liver cirrhosis and liver cancer is high and entirely preventable.
Health agencies should develop population-based policies to
reduce levels of harmful and/or hazardous consumption and pro-
vide ﬁnancial support for research aimed at developing improved
therapies for patients with ALD [2,16]. Public health policies
should include taxation escalations for alcoholic beverages that
should be partially used to cover patient costs and to develop
new therapies for alcohol use disorders and ALD. Several
approaches have been used, including policies to decrease avail-
ability of alcohol by limiting the hours and places of sale and
establish minimum age purchase laws [2]. Moreover, several
studies have shown that the rising price of alcohol decreases
morbidity and mortality [24,25]. The advent of cheap alcohol
has had a particularly deleterious effect in the UK and Ireland,
which have, in turn, lead to efforts to curb excess consumption
by raising the minimum price of alcohol or banning the sale of
alcohol below cost (in England and Wales). Recent modeling5 vol. 62 j S38–S46 S39
Review
studies suggest that the former method is more likely to be effec-
tive [26]. Other more nuanced approaches may be necessary in
societies where alcohol use is linked to production within the
family home, especially in Eastern Europe.Natural history of alcoholic liver disease: from steatosis to
cirrhosis
The spectrum of ALD comprises simple steatosis, alcoholic steato-
hepatitis (ASH), progressive ﬁbrosis, cirrhosis and the develop-
ment of HCC Fig. 2. Several studies suggested that incidence of
HCC is lower in alcoholic cirrhosis than in viral cirrhosis. The risk
of HCC persists in cirrhotic patients even among those that
remain abstinent. Although up to 90% of heavy drinkers develop
steatosis, only a minority of those with steatosis progress to ASH
and 10–20% eventually develop cirrhosis [27,28]. Steatosis is usu-
ally asymptomatic and rapidly reversible with abstinence [28].
Continued heavy alcohol consumption, however, leads in some
patients to liver inﬂammation characterized by the inﬁltration
of polymorphonuclear cells (PMN), hepatocyte damage
often described as ballooning, and Mallory-Denk’s bodies, both
of which deﬁne ASH. Some patients develop liver ﬁbrosis
(20–40%) and cirrhosis (10–20%), which confers a high risk of
complications (ascites, variceal bleeding, hepatic encephalopa-
thy, renal failure and bacterial infections) [29,30].
In the last decades, major advances have been made in our
understanding of the factors that inﬂuence ALD progressionSteatosis 
Fibrosis
Normal liver 
20-40%    
80-90%    
Alcoholic  
steatohepatitis 
AH 
Contributes to disease
progression
SILENT
Fig. 2. Natural history of alcoholic liver disease from steatosis to cirrhosis and hepat
from one stage to the next. Most patients with persistent alcohol abuse develop some d
develops, ultimately resulting in cirrhosis. Cirrhosis can lead to severe complications
bacterial infections and also predisposes to HCC. The development of alcoholic steatohep
this develops in patients with severe disease it results in AH.
S40 Journal of Hepatology 201[31–34]. The natural history of ALD cannot be separated from
the natural history of alcoholism. Alcohol use, remission and
relapse comes in many different patterns and needs to be
observed over many years [35]. This applies both to those in pos-
session of their native liver, and the post-transplant patient with
alcoholism [36]. Disease progression varies according to genetic
and environmental factors. The major link of people with a
genetic predisposition to develop ALD is supported by the obser-
vation of concordance rates for alcoholism and alcohol-induced
liver ﬁbrosis in monozygotic twins of 26.3 and 14.6, respectively
[37]. Recent studies observed that variations in PNPLA3, which
encodes patatin-like phospholipase domain-containing protein
3, strongly inﬂuence the development of advanced liver ﬁbrosis
among Mexican and Caucasian populations [37–40].
Importantly, PNPLA3 polymorphisms can be considered to be
the only conﬁrmed and replicated genetic risk factor for ALD.
This genetic factor also inﬂuences the development of HCC [41].
Despite the large number of studies that have assessed the role
of genetic variation in susceptibility to ALD, a large-scale
genome-wide association study of factors associated with
ALD remains to be performed given the potential biases of
previous studies [42]. Most published reports include a limited
number of patients who lack a well-deﬁned phenotype, the
investigation of only a few genes and have crucial methodological
weaknesses.
Although several translational studies have evaluated the risk
of cirrhosis, the natural history of ALD remains only partially
explored due to the lack of prospective studies of large cohorts 
Cirrhosis 
8-20%    
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3-10%    
Decompensation
(+ infections)
20-40%    
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ocellular carcinoma (HCC). The percentage represents the patients who progress
egree of hepatic steatosis. If the alcohol abuse persists, liver ﬁbrosis progressively
related to portal hypertension (ascites, variceal bleeding and encephalopathy),
atitis (ASH) predisposes patients to progress to advanced liver ﬁbrosis, and when
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with the goal of assessing progression of liver damage. A transla-
tional study comprising over 2000 hospitalized excessive heavy
drinkers with modiﬁed results in liver laboratory tests investi-
gated by liver biopsy showed that 34% of these subjects pre-
sented with alcohol-induced cirrhosis, 46% with fatty liver
with/without ﬁbrosis, 9% with acute alcohol-induced hepatitis
and 11% with a normal liver [43]. When the progression of ﬁbro-
sis was expressed in terms of duration of exposure, the progres-
sion of ﬁbrosis was estimated by dividing the ﬁbrosis score by the
time of exposure. In heavy drinkers, the risk of cirrhosis reached
50% at 61 years of age, and the likelihood of developing cirrhosis
in 50% of cases was observed after 35 years, with a shorter time of
progression to cirrhosis among women than men [44]. Based on
an analysis of all the published data, cirrhosis occurs in approxi-
mately 20% of hospitalized patients with excessive alcohol
consumption.
The presence of steatosis typically precedes the development
of ﬁbrosis [45] but the inﬂuence of fat accumulation on progres-
sion of ﬁbrosis is not well known. The long-term survival of
patients with isolated steatosis is clearly reduced compared to
that of abstinent controls. After a mean follow-up of approxi-
mately 10 years, patients with alcoholic steatosis died more fre-
quently than those with non-alcoholic fatty liver disease (74%
vs. 25%) and more patients developed cirrhosis (21% vs. 1%)
[46]. Twenty-ﬁve percent of the observed deaths among heavy
drinkers were associated with cirrhosis and 75% were attributed
to other diseases related to alcohol.
Patients with underlying severe ﬁbrosis or cirrhosis and heavy
alcohol intake can present a form of acute-on-chronic liver failure
called alcoholic hepatitis (AH) [29]. This is characterized by an
abrupt rise in serum bilirubin levels, jaundice and liver-related
complications. Previously, it was considered that AH could occur
in patients with mild underlying liver disease. However, more
recent studies using tru-cut needles have shown that the major-
ity of patients with severe AH have underlying cirrhosis [47].
Patients with severe forms of AH show high short-term mortality
around 30–50% at 3 months. Patients with AH disclosed the fast-
est progression of ﬁbrosis and consequently an increased risk of
liver-related death [45]. Among other factors, obesity is an
independent risk factor for progression to cirrhosis. Heavy drin-
kers who are overweight for at least 10 years have a 2-fold risk
of developing cirrhosis [43]. While it is not surprising that obesity
predisposes to alcohol-induced fatty liver, it is somehow surpris-
ing that it favors the development of AH. This association sug-
gests that insulin resistance probably exacerbates the
deleterious effects of alcohol in the liver. In fact, hyperglycemia
is an independent predictor of progression of ﬁbrosis in heavy
drinkers [48]. Finally, there are some reports suggesting that
moderate drinking may have beneﬁcial effect on the livers of
obese subjects [49].
There is a clear need to perform prospective large follow-up
studies to identify the main genetic and environmental factors
that inﬂuence disease progression in patients with ALD. There
are few clinical trials in patients with early forms of ALD and
the natural history of this disease is poorly understood. Disease
progression is usually silent until heavy drinkers develop jaun-
dice or liver decompensation that, in many cases, occurs in the
context of an episode of AH. The course of ALD frequently alter-
nates between periods of complications and liver failure due to
excessive drinking and compensated disease as a result of periods
of alcohol abstinence.Journal of Hepatology 201Diagnosis of alcoholic liver disease
In its early stages, ALD is a silent disease and can only be detected
by laboratory tests or imaging techniques. There are few pro-
grams aimed at early detection of ALD at its asymptomatic stages.
Some patients with early ALD can show stigmata of alcohol abuse
such as bilateral parotid gland hypertrophy, muscle wasting,
malnutrition, Dupuytren’s sign, and signs of peripheral neuropa-
thy. In patients with cirrhosis, most physical ﬁndings are not
speciﬁc of the etiology. However, some signs such as gynecomas-
tia and extensive spider angiomas may be more frequently seen
in those with alcohol as the main cause of liver disease. The
diagnosis of ALD is frequently suspected upon documentation
of excessive alcohol consumption (>40–50 g/day) and the pres-
ence of clinical and/or biological abnormalities suggestive of liver
injury. Laboratory blood tests such as mean corpuscular volume,
gamma glutamyl transpeptidase (GGT) and aspartate amino
transferase (AST) can indicate early ALD whereas advanced ALD
is suspected if there is decreased albumin, increased INR, ele-
vated bilirubin level or low platelet count. There are several lab-
oratory markers that estimate persistent alcohol intake. Among
them, carbohydrate deﬁcient transferrin and GGT are the most
frequently used markers to detect previous alcohol consumption
[50]. In patients with ALD, the AST/ALT ratio typically is greater
than 1 [51]. This ratio is typically greater than 2 in AH and can
also be found in patients with advanced cirrhosis regardless of
the etiology.
Liver biopsy is not clearly indicated in patients with early
stages of ALD or when established cirrhosis is revealed by clinical,
analytical and imaging data. The liver biopsy can be done per-
cutaneously in most patients but requires a transjugular
approach in patients with a low platelet count and/or a prolonged
prothrombin time. The precise indications of liver biopsy are not
well established in routine practice. However, it is suggested in
patients with aggressive forms of ALD such as AH requiring speci-
ﬁc therapies (e.g., corticosteroids and/or pentoxifylline) and in
patients with other cofactors suspected of contributing to liver
disease. In the setting of clinical trials, the assessment of liver his-
tology by performing a liver biopsy is recommended. The typical
ﬁndings in patients with ALD include steatosis, hepatocellular
damage (ballooning and/or Mallory-Denk bodies), an inﬂamma-
tory inﬁltrate basically composed of PMN cells that predominates
in the lobules, and a variable degree of ﬁbrosis and lobular distor-
tion that may progress to cirrhosis [52].
For the assessment of liver ﬁbrosis in patients with ALD, there
are non-invasive methods including serum markers and liver
stiffness measurements. Most non-invasive tests have been lar-
gely validated in patients with hepatitis C, while few studies have
included patients with ALD. Thus, AST to platelet ratio index
(APRI), FibroTest, Fibrometer, Hepascore, and Fibrosure can
be useful in patients with ALD [53]. They are useful to distinguish
between mild and severe ﬁbrosis, but have limited utility in
intermediate degrees of ﬁbrosis. In terms of prognostic value,
FibroTest (AUROC for survival = 0.79 ± 0.04), Fibrometer
(0.80 ± 0.04) and Hepascore (0.78 ± 0.04) had a prognostic value
equivalent to liver biopsy (0.77 ± 0.04) [54]. Transient elas-
tography (FibroScan) is commonly used to assess ﬁbrosis in
patients with chronic liver disease. FibroScan calculates an esti-
mate, expressed in kPa (kilopascals), for the stiffness from the
measurement of wave velocity. The diagnostic threshold with
the optimal diagnostic value for the detection of cirrhosis varies5 vol. 62 j S38–S46 S41
AHHS for prognostic stratification of AH
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Fig. 3. The Alcoholic Hepatitis Histological Score (AHHS) allows prognostic
stratiﬁcation of patients with biopsy-proven AH. AHHS categories are as
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between 12.5 and 14.6 kPa in studies including chronic hepatitis
C [55]. The diagnostic value of FibroScan for the detection of cir-
rhosis has been evaluated in excessive drinkers in two indepen-
dent studies [56,57]. In these studies, the elasticity was
correlated with ﬁbrosis stage and the diagnostic value of
FibroScan conﬁrmed by AUROC close to 0.9. The optimal thresh-
olds for the diagnosis of cirrhosis were respectively 19.5 and
22.6 kPa [56,57]. It is important to note that these thresholds,
although close together, are very different from those proposed
for the detection of cirrhosis in chronic carriers of the hepatitis
B and C virus. Of note, elevated liver stiffness values in patients
with ALD and AST serum levels >100 U/L should be interpreted
with caution because of the possibility of falsely elevated liver
stiffness as a result of superimposed ASH [58]. Moreover, recent
alcohol consumption can also elevate liver stiffness, perhaps
related to the vasodilatory effects of alcohol [59]. Imaging tech-
niques can also be used to assess the severity of ALD.
Ultrasonography, MRI, and CT are useful to detect fatty liver,
advanced ﬁbrosis/cirrhosis as well as signs of portal hypertension
[60]. Moreover, they are useful for the screening and assessment
of complications such as ascites and portal vein thrombosis.
Among those methods, ultrasound is the most used due to its
low cost. However, its sensitivity and speciﬁcity is low especially
when steatosis is mild. MRI and MR spectroscopy are reliable
tools for assessing the amount of steatosis but their use is limited
by high cost [61].follows: mild, 0–3; intermediate, 4–5; severe, 6–9. The Kaplan-Maier graph
shows 90-day survival in each the three categories. Reproduced with permission
from [47].Management of alcoholic hepatitis
Providing more efﬁcacious therapies for patients with AH is one
of the most urgent needs in clinical hepatology. The current ﬁrst
line therapy (i.e. prednisolone) was proposed in 1971, but novel
targeted therapies are needed [62]. Currently, there are no reli-
able non-invasive diagnostic tools for AH in patients with decom-
pensated ALD. The classical proﬁle of AH comprises elevated
serum AST up to twice the upper limit of the normal range,
although rarely above 300 IU/ml, with an AST/ALT ratio typically
greater than 2 [29,63]. Biological parameters indicating impaired
liver function include hypoalbuminemia, elevated bilirubin, high
INR and prothrombin time. The presence of acute kidney injury,
often due to superimposed hepatorenal syndrome, is associated
with a high risk of death [29,64]. In addition, patients with AH
frequently disclose leukocytosis and elevated temperature result-
ing from a systemic inﬂammatory response syndrome.
In routine practice as in many published clinical trials, the
diagnosis of AH relies on clinical and biological criteria.
However, such strategy carries a 10–50% risk of misclassifying
patients with or without ASH [65–67]. In the setting of clinical
trials, the diagnosis of AH through liver biopsy has been recom-
mended by EASL guidelines [2], and liver biopsy may be consid-
ered in patients with aggressive forms of ALD requiring speciﬁc
interventions or when the diagnosis remains in doubt. A tran-
sjugular route is often preferred due to frequent coexisting
ascites and/or coagulopathy. Recently, a histological scoring sys-
tem has been proposed for predicting short-term survival in
patients with AH. The resulting Alcoholic Hepatitis Histological
Score comprises four parameters that are independently asso-
ciated with patients’ survival: ﬁbrosis stage, PMN inﬁltration,
type of bilirubinostasis and the presence of megamitochondria
(Fig. 3). By combining these parameters in a semi-quantitativeS42 Journal of Hepatology 201manner, this histological score is able to stratify patients into
low, intermediate, or high risk for death within 90 days [47].
Viral hepatitis and bacterial infections should be ruled out,
particularly spontaneous bacterial peritonitis. Importantly, the
clinical manifestations of spontaneous bacterial peritonitis and
the episode of AH are often similar (abdominal pain, fever, leuko-
cytosis). Doppler ultrasound is required to exclude biliary or vas-
cular disorders and HCC. Severe AH may progress to multisystem
organ failure and as mentioned above the advent of acute kidney
injury is associated with a bad prognosis [68]. In this setting, the
use of AKIN criteria for acute kidney injury is more sensitive than
the traditional criteria of renal failure (i.e. creatinine >1.5 mg/dl)
for predicting multiorgan dysfunction and death [69]. AH
patients are also at risk of acute kidney injury due to the use of
nephrotoxic radiocontrast agents, aminoglycosides and non-ster-
oidal anti-inﬂammatories.
Signiﬁcant mortality and morbidity in Europe and North
America are attributable to AH [70,71], with around 57,000 hos-
pital admissions for AH in the US in 2007, which accounted to
0.71% of all admissions [70,71]. However, the diagnosis of AH is
frequently overlooked, especially in patients admitted for gas-
trointestinal bleeding or sepsis. In-hospital mortality ﬂuctuates
from 6.8% to 15% [70,71]. Patients at signiﬁcant risk of early death
can be identiﬁed by prognostic models. The available prognostic
models include the Maddrey’s discriminant function (DF), the
Model for End-Stage Liver Disease (MELD), the Glasgow AH
(GAH) score, and the ABIC score [72–74]. The most widely used
is the DF, which is calculated as 4.6  (prothrombin time
patient  prothrombin time control) + serum bilirubin [75]. A
DF value P32 is indicative of evaluated short-term mortality
around 20–35% at 1 month. The MELD discloses accuracy similar5 vol. 62 j S38–S46
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to DF [73] and a MELD of 21 has 75% sensitivity and speciﬁcity in
predicting 90-day mortality. The GAH score incorporates age,
serum bilirubin, blood urea nitrogen, prothrombin time, and
peripheral white blood cell count, and has been shown to accu-
rately predict 28-day mortality [74]. The ABIC uses age, bilirubin,
INR, and creatinine to estimate a 90-day risk of mortality, and can
categorize patients into low (0%), intermediate (30%), and high
(75%) risk of death [72]. The MELD has been evaluated in US
cohorts, the GAH in populations from the UK, and the ABIC in
Spain.
Early identiﬁcation of patients with a substantial improve-
ment in hepatic function is of interest in the management of sev-
ere AH [76]. After 7 days of medical therapy with prednisolone,
physicians may identify responders using the Lille model [76].
The Lille model is highly predictive of death at 6 months and a
score above 0.45 predicted 75% of deaths [76,77]. Clinical practice
guidelines therefore recommend stopping corticosteroids after
one week in those with an unfavorable Lille score, as the risks
of continued therapy likely outweigh the beneﬁts [2,76,78].
The therapeutic management of AH patients includes general
and speciﬁc measures. The achievement of alcohol abstinence is
the cornerstone of treatment of AH patients and requires active
management of alcohol use disorders. Symptoms of alcohol with-
drawal should be monitored, prevented and treated. Intensive
nutritional intervention is required to correct protein-calorie
malnutrition [79] through high calorie meals and supplements,
or through enteral feedings if necessary and thiamine should be
administered when considering the increased risk of Wernicke’s
encephalopathy in alcoholic patients [80]. Patients with severe
AH should be admitted for initial management when considering
the increased risk of early deaths, and often need admission to an
intensive care unit. Infections are exceedingly common in severe
AH [78] and should be routinely screened with at least chest x-
ray, urinoanalysis, and cultures of blood, urine and ascites [78].
Empiric antibiotics may be administered if there is a high suspi-
cion of infection. Prevention of acute kidney injury, another fre-
quent complication indicating increased risk of early mortality
[64], should be performed using volume expansion with crystal-
loid/albumin. Interestingly, patients with systemic inﬂammatory
response are at high risk of developing acute kidney injury [64].
The European and American guidelines proposed pred-
nisolone or pentoxifylline [81] as ﬁrst line therapeutic options
for patients with severe AH [82,83]. However, two recent studies
called into question the use of pentoxifylline. A head-to-head
randomized study showed that the use of pentoxifylline does
not have beneﬁcial effects on survival compared to prednisolone
[84]. In a large randomized controlled trial (STOPAH) that
includes more than 1000 patients that was presented during
the 2014 AASLD The Liver Meeting, pentoxifylline was no better
than placebo in terms of short-term mortality [85]. However, this
study excluded patients with more severe forms of AH (acute kid-
ney injury, severe sepsis, severe encephalopathy, etc.). Therefore,
it is unclear if pentoxifylline is also ineffective in patients with
very severe forms.
Corticosteroids have been used in the treatment of AH for
more than 40 years [75,86–90]. The most studied formulation is
prednisolone 40 mg daily for one month, with or without a taper.
Although the clinical trials suffer from heterogeneity and high
risk of bias, a meta-analysis from individual data observed that
corticosteroids improved survival in patients with a high DF
[91]. This study conﬁrmed the need for adapting corticosteroidJournal of Hepatology 201therapy to response to treatment. A subgroup analysis was per-
formed according to the percentile distribution of the Lille score.
This approach identiﬁed three patterns of responses; complete,
partial and null, with signiﬁcant differences in survival beneﬁt:
91% vs. 79% vs. 53%, respectively. Survival impact of corticos-
teroids was signiﬁcant in complete and partial responders,
whereas it appeared negligible in null responders [91]. This
new classiﬁcation raises questions concerning management of
severe AH. There are two issues that should be raised. First, the
survival beneﬁt from corticosteroid therapy is transient, as sug-
gested by the recent STOPAH trial [85]. And second, the use of
prednisolone increases the risk of pulmonary infections, espe-
cially invasive aspergillosis [92]. Therefore, it is important to
develop new therapies that offer a sustained response and do
not favor potentially lethal infections.
It seems clear that corticosteroids may be sufﬁcient in com-
plete responders and that novel pharmacological therapies are
required for intermediate responders. Several attempts have been
made to combine steroids with other drugs. The combination of
both pentoxifylline and prednisolone offers no beneﬁt [93] and
there are no available rescue medical therapies for non-respon-
ders [29,77]. A recent randomized trial showed that the combina-
tion of N-acetylcysteine with prednisolone reduced 1-month
mortality (8% vs. 24%) and incidence of hepatorenal syndrome
and infection [94]. The favorable safety proﬁle of N-acetylcys-
teine makes it an appealing option, although conﬁrmatory stud-
ies are needed. In non-responders to corticosteroids, a liver
transplantation was traditionally contraindicated, since patients
could not complete a 6-month period of abstinence. When fol-
lowing a strict 6-month rule for transplant eligibility, most
patients die before a transplant can be indicated [95]. This fact
prompted several experts in the ﬁeld to challenge this policy
and to perform a prospective study of early liver transplantation
in highly selected patients with good social support and positive
prognosis from a psychological point of view. Performing a sal-
vage liver transplant in selected patients with AH non-respond-
ing to medical therapy dramatically improve survival [96].
These results support future evaluation of early liver trans-
plantation in a carefully-selected subgroup of patients with sev-
ere AH non-responding to medical therapy [2]. This
controversial indication is increasingly being accepted by liver
centers yet conﬁrmatory studies are needed.Liver transplantation in alcoholic cirrhotic patients
ALD is a major indication for liver transplantation worldwide.
Patients needing a transplant due to ALD often present at the
time of transplantation multisystemic effects of long-term etha-
nol abuse [97]. These comorbidities include malnutrition, vitamin
deﬁciencies, non-immune hemolytic anemia, peripheral and cen-
tral neural system abnormalities, nephropathy, muscle wasting
due to alcoholic myopathy, and others. Therefore, the integral
care of the transplanted patient with ALD ideally requires a mul-
tidisciplinary approach.
Most liver programs require a 6-month period of abstinence
prior to evaluation of alcoholic patients [82,98,99]. The rationale
of this strategy is to allow disease regression in patients with
recent alcohol abstinence and to ensure proper alcohol counsel-
ing in order to prevent relapse after the liver transplantation.
As for other causes of decompensated liver disease, patients are5 vol. 62 j S38–S46 S43
Review
listed if the MELD score isP15. In patients with ALD, the survival
beneﬁt among transplant recipients arises only from this thresh-
old [100]. Alcohol abstinence is a critical issue and drinking
habits of transplanted patients need to be routinely screened by
physicians with tools of proven reliability. However, there is no
consensus concerning the deﬁnition of alcohol relapse
[101,102]. For some experts, any drinking is considered a relapse,
whereas others have deﬁned excessive drinking as relapse
because only this drinking pattern is associated with alcohol-in-
duced liver injury. The deﬁnition of a relapse as any alcohol
intake after liver transplantation contrasts with the literature
on addiction medicine in which relapse is considered only in
the presence of heavy drinking recurrence. This lack of consensus
in deﬁnition of alcohol relapse explains why the rate of relapse
after liver transplantation varies among studies ranging from
10% to 50% [103,104]. A meta-analysis showed no differences in
the proportion of transplant recipients with ALD that drank after
a liver transplant compared with those with non-ALD: 4% vs. 5%
at 6 months and 17% vs. 16% at 12 months [105]. However, trans-
plant patients with ALD were more likely to drink excessively
[105]. In terms of liver injury, occasional or moderately heavy
drinking does not impact graft function or patient survival
[106,107] whereas the deleterious effect of excessive drinking
is established at long-term. Indeed, recipients who resume abu-
sive drinking have shorter long-term survival than abstinent
recipients or patients with minor relapse [108] and recurrence
of ALD is the main cause of death.
Mortality and morbidity after liver transplantation in ALD
patients is similar to patients with other etiologies [109]. A recent
study demonstrated that survival outcome of living donor liver
transplantation in ALD patients is comparable with that of
deceased donor liver transplantation. Interestingly, less than 2%
of patients died of alcohol abuse, suggesting that alcohol relapse
is not a major problem in patients receiving a living donor liver
transplantation [110]. The cause of death after transplantation
for ALD differs compared to non-ALD recipients. In particular, car-
diovascular causes and de novo malignancies are signiﬁcantly
over-represented in the patients transplanted for ALD [111].
There is not a clear association between new-onset cancers and
alcohol relapse, suggesting that other environmental factors such
as cigarette smoking and obesity can certainly play a role.
There are few data demonstrating the effectiveness of preven-
tive measures in the development of comorbidities in these
patients. Psychosocial efforts during the pre- and post-liver trans-
plantation periods should be focused not only on alcohol relapse
but also on preventing and treating modiﬁable risk factors such
as obesity and cigarette smoking. A recent proof of concept study
showed that smoking withdrawal after liver transplantation had
a protective effect against the development of neoplasia in ALD
transplant patients [112]. Further studies assessing the impact
of speciﬁc measures and programs for smoking cessation should
be performed in this patient population.
There is a current trend to tailor the immunosuppression in
patients with ALD by minimizing the exposure to calcineurin
inhibitors and promoting the use of mTOR inhibitors (rapamycin
and everolimus). The rationale is that calcineurin inhibitors are
known to favor cardiovascular events and mTOR inhibitors may
promote decreased tumor growth and angiogenesis. Although
some recent retrospective studies support this strategy in
patients with ALD [113], well-designed studies should assess
the optimal immunosuppressive regimens in these patients.S44 Journal of Hepatology 201Financial support
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